

~~Judy~~

please do not
include *

Appl. No. 09/889,300

AMENDMENTS TO THE CLAIMS

- a m end* 7
1. (Currently Amended) A pharmaceutical composition for treatment of cancer disease comprising a ~~first~~ antibody directed against the cellular membrane antigen Ep-CAM and at least one ~~vaccine~~ adjuvant, wherein said first antibody is a murine monoclonal antibody, wherein the variable region of the heavy chain is the amino acid sequence as shown in SEQ ID NO: 1 and wherein the variable region of the light chain is the amino acid sequence as shown in SEQ ID NO: 2.
 2. (Canceled)
 3. (Canceled)
 4. (Canceled)
 5. (Currently Amended) The pharmaceutical composition of any one of claims 1-3 claim 1, wherein said first antibody has the same specificity of binding as that antibody defined in claim [4]1.
 6. (Previously Presented) The pharmaceutical composition of claim 1, further comprising at least a second antibody directed against a different membrane antigen or against a different epitope of said Ep-CAM membrane antigen.
2
 7. (Previously Presented) The pharmaceutical composition of claim 1, wherein said first antibody is contained in a dosage range of 0.01 - 4 mg.
3
 8. (Previously Presented) A method of treating cancer disease comprising administering to a patient in need thereof the pharmaceutical composition of claim 1.

Appl. No. 09/889,300

4
9. (Previously Presented) The method according to claim 8, wherein said pharmaceutical composition is administered by subcutaneous, intradermal or intramuscular injection.

3

10. (Cancelled)

11. (Cancelled)

5
12. (Currently Amended) The method of claim 8 or 10, wherein said first antibody is administered at a dosage in the range of 0.01 to 4 mg antibody.

3 4

13. (Cancelled)

6
14. (Previously Presented) The method according to claim 12, wherein said dosage is 0.5 mg antibody.

5